Following the successful conclusion of trials into Erbitux for head and neck cancer, ImClone says it will seek expanded use of the cancer drug in the third quarter. Erbitux is currently indicated for colorectal cancer. Story [1]
Links:
[1] http://www.thestreet.com/_googlen/stocks/biotech/10228715.html?cm_ven=GOOGLEN&cm_cat=FREE&cm_ite=NA